Literature DB >> 7693940

Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process.

K Aho1, R von Essen, P Kurki, T Palosuo, M Heliövaara.   

Abstract

OBJECTIVE: Antikeratin antibody (AKA) and antiperinuclear factor (APF) are antibodies characteristic for rheumatoid arthritis (RA). Our purpose was to obtain information on the occurrence of APF before the onset of clinical disease and on the occurrence of AKA and APF in cases with false-positive rheumatoid factor (RF) reactions.
METHODS: AKA and APF were measured with indirect immunofluorescence technique using rat esophagus and buccal mucosa cells, respectively, as antigen source.
RESULTS: Five of 30 preillness specimens from subjects who later developed seropositive RA were positive for AKA and APF, 3 sera were positive for only AKA and 3 for only APF. All the eleven sera positive for AKA or APF were RF positive. Both AKA and APF were detected in 6 of 70 sera from RF positive subjects who did not develop RA within a 10-year followup, 3 sera were positive for only AKA and 3 for only APF.
CONCLUSION: AKA and APF appear to be linked markers of an immunological process which, in RF positive subjects, predicts the development of clinical arthritis. However, disease manifestations develop in only a proportion of cases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693940

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  31 in total

1.  The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies.

Authors:  M Sebbag; M Simon; C Vincent; C Masson-Bessière; E Girbal; J J Durieux; G Serre
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

Review 2.  Vitamin D in rheumatoid arthritis-towards clinical application.

Authors:  Louisa E Jeffery; Karim Raza; Martin Hewison
Journal:  Nat Rev Rheumatol       Date:  2015-10-13       Impact factor: 20.543

3.  The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner.

Authors:  Kevin D Deane; Colin I O'Donnell; Wolfgang Hueber; Darcy S Majka; Ann A Lazar; Lezlie A Derber; William R Gilliland; Jess D Edison; Jill M Norris; William H Robinson; V Michael Holers
Journal:  Arthritis Rheum       Date:  2010-11

Review 4.  Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention.

Authors:  Kevin D Deane
Journal:  Curr Rheumatol Rep       Date:  2018-06-26       Impact factor: 4.592

Review 5.  Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Nat Rev Rheumatol       Date:  2015-02-17       Impact factor: 20.543

6.  Anti-microtubule organizing center with microtubule by autoimmune target test is also useful serological marker in rheumatoid arthritis evaluation.

Authors:  Duck-An Kim; Think-You Kim
Journal:  Rheumatol Int       Date:  2011-11-19       Impact factor: 2.631

Review 7.  Prevention of rheumatic diseases: strategies, caveats, and future directions.

Authors:  Axel Finckh; Kevin D Deane
Journal:  Rheum Dis Clin North Am       Date:  2014-09-04       Impact factor: 2.670

8.  Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis.

Authors:  Marja-Kaisa Koivula; Markku Heliövaara; Jarmo Ramberg; Paul Knekt; Harri Rissanen; Timo Palosuo; Juha Risteli
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

9.  Antiperinuclear factor: a useful test for the diagnosis of rheumatoid arthritis.

Authors:  S Muñoz-Fernández; R Alvarez-Doforno; M Cuesta; A Balsa; G Fontán; J Gijón-Baños
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

Review 10.  Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE.

Authors:  Kevin D Deane; Hani El-Gabalawy
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.